TCGA-CQ-A4CB-01A-11R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- MYC_TARGETS_V2+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- G2M_CHECKPOINT+0.470
- ANGIOGENESIS+0.450
- MYC_TARGETS_V1+0.450
- INTERFERON_ALPHA_RESPONSE+0.400
- INFLAMMATORY_RESPONSE+0.380
- IL6_JAK_STAT3_SIGNALING+0.360
- INTERFERON_GAMMA_RESPONSE+0.320
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.310
- PEROXISOME-0.310
- CHOLESTEROL_HOMEOSTASIS-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- BILE_ACID_METABOLISM-0.290
- MYOGENESIS-0.270
- OXIDATIVE_PHOSPHORYLATION-0.270
- HEME_METABOLISM-0.230
- KRAS_SIGNALING_DN-0.190
- ADIPOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.856 |
| 2 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.835 |
| 3 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.827 |
| 4 | SRR650184 | — | — | 0.826 |
| 5 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.825 |
| 6 | SRR650185 | — | — | 0.824 |
| 7 | SRR8943028 | — | — | 0.823 |
| 8 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.823 |
| 9 | F5EB77B4-61AD-40EC-B5B0-44D2D5AD66D7 | — | — | 0.817 |
| 10 | SRR934732 | — | — | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |